Bone Biologics CorpBBLGEarnings & Financial Report
Nasdaq
NextMar 31, 2026
BBLG Q1 2024 Key Financial Metrics
Revenue
$255
Gross Profit
N/A
Operating Profit
$-903.5K
Net Profit
$-866.0K
Gross Margin
N/A
Operating Margin
-354327.8%
Net Margin
-339596.1%
YoY Growth
-54.1%
EPS
$-1.31
Financial Flow
Bone Biologics Corp Q1 2024 Financial Summary
Bone Biologics Corp reported revenue of $255 for Q1 2024, with a net profit of $-866.0K (-339596.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $255 |
|---|---|
| Net Profit | $-866.0K |
| Gross Margin | N/A |
| Operating Margin | -354327.8% |
| Report Period | Q1 2024 |
Bone Biologics Corp Annual Revenue by Year
Bone Biologics Corp annual revenue history includes year-by-year totals (for example, 2023 revenue was $1.9K).
| Year | Annual Revenue |
|---|---|
| 2023 | $1.9K |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|
| Revenue | $556 | $428 | $536 | $348 | $255 |
| YoY Growth | N/A | N/A | N/A | N/A | -54.1% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|
| Assets | $6.8M | $7.6M | $5.0M | $3.7M | $3.8M |
| Liabilities | $4.0M | $1.9M | $1.2M | $831402 | $164626 |
| Equity | $2.8M | $5.7M | $3.8M | $2.9M | $3.7M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|
| Operating CF | $-1.3M | $-3.6M | $-2.6M | $-2.0M | $-1.3M |